{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:14:53Z","timestamp":1761156893907,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In the present study we evaluated how systemic arterial hypertension (SAH), dyslipidemia and diabetes mellitus influence the efficacy, safety and retention rate of biological disease-modifying anti-rheumatic drug (bDMARD) treatment in rheumatic musculoskeletal disorders (RMDs). The charts of RMD patients treated with the first-line bDMARD were reviewed, collecting data on safety, efficacy and comorbidities at prescription (baseline, BL), after 6 months (6M) and at last observation on bDMARD (last observation time, LoT). In 383 RMD patients, a higher rate of adverse events at 6M (p = 0.0402) and at LoT (p = 0.0462) was present in dyslipidemic patients. Patients who developed dyslipidemia or SAH during bDMARD treatment had similar results (dyslipidemia p = 0.0007; SAH p = 0.0319) with a longer bDMARD retention as well (dyslipidemia p &lt; 0.0001; SAH p &lt; 0.0001). SAH patients on angiotensin converting enzyme inhibitors (ACEis) or angiotensin-II receptor blockers (ARBs) continued bDMARDs for longer than non-exposed patients (p = 0.001), with higher frequency of drug interruption for long-standing remission rather than inefficacy or adverse reactions (p = 0.0258). Similarly, dyslipidemic patients on statins had a better bDMARD retention than not-exposed patients (p = 0.0420). In conclusion, SAH and dyslipidemia may be associated with higher frequency of adverse events but a better drug retention of first-line bDMARD in RMDs, suggesting an additional effect of ACEis\/ARBs or statins on the inflammatory process and supporting their use in RMD bDMARD patients with SAH\/dyslipidemia.<\/jats:p>","DOI":"10.3390\/jcm9051310","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T06:41:20Z","timestamp":1588660880000},"page":"1310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-5025","authenticated-orcid":false,"given":"Laura","family":"Cometi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-2083","authenticated-orcid":false,"given":"Cosimo","family":"Bruni","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Chiti","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Tofani","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-9785","authenticated-orcid":false,"given":"Francesca","family":"Nacci","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bartoli","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bellando-Randone","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"},{"name":"Department of Geriatric Medicine, Division of Rheumatology Azienda Ospedaliera Universitaria Careggi, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Melchiorre","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"},{"name":"Department of Geriatric Medicine, Division of Rheumatology Azienda Ospedaliera Universitaria Careggi, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginevra","family":"Fiori","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Division of Rheumatology Azienda Ospedaliera Universitaria Careggi, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"},{"name":"Department of Geriatric Medicine, Division of Rheumatology Azienda Ospedaliera Universitaria Careggi, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Via delle Oblate 4, 50141 Florence, Italy"},{"name":"Department of Geriatric Medicine, Division of Rheumatology Azienda Ospedaliera Universitaria Careggi, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/jhh.2013.80","article-title":"Infliximab, a TNF-a inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients","volume":"28","author":"Yoshida","year":"2014","journal-title":"J. Hum. Hypertens."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/08037051.2016.1183460","article-title":"Effect of tumor necrosis factor-\u03b1 inhibitors on ambulatory 24-h blood pressure","volume":"26","author":"Grossman","year":"2017","journal-title":"Blood Press."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10067-010-1405-7","article-title":"A systematic review of the effect of TNF-\u03b1 antagonists on lipid profiles in patients with rheumatoid arthritis","volume":"29","author":"Pollono","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: A meta-analysis","volume":"41","author":"Peters","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: A systematic review with meta-analysis","volume":"71","author":"Duny","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1196\/annals.1351.039","article-title":"Effects of anti-TNF treatment on lipid profile in patients with active rheumatoid arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and Tofacitinib in randomized clinical trials. A systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","first-page":"83","article-title":"Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis","volume":"24","author":"Martin","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: An approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/acr.21978","article-title":"Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients","volume":"65","author":"Heimans","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12467","article-title":"Angiotensin II in inflammation, immunity and rheumatoid arthritis","volume":"179","author":"Chang","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1592\/phco.2005.25.9.1213","article-title":"Protective effects of angiotensin II interruption:evidence for antiinflammatory actions","volume":"25","author":"Dagenais","year":"2005","journal-title":"Pharmacotheray"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.1038\/s41598-017-13746-w","article-title":"Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium","volume":"7","author":"Terenzi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(84)91821-X","article-title":"Captopril: A new treatment for rheumatoid arthritis?","volume":"1","author":"Martin","year":"1984","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1210\/jc.2002-021836","article-title":"Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kB, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action","volume":"88","author":"Dandona","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","article-title":"The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials","volume":"17","author":"Li","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lillegraven, S., Greenberg, J.D., Reed, G.W., Saunders, K., Curtis, J.R., Harrold, L., Hochberg, M.C., Pappas, D.A., Kremer, J.M., and Solomon, D.H. (2019). Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210459"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/5\/1310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:32:28Z","timestamp":1760362348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/5\/1310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["jcm9051310"],"URL":"https:\/\/doi.org\/10.3390\/jcm9051310","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,5,2]]}}}